ATX-295

· Accent Therapeutics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ATX-295, covering 2026-02-24 to 2026-02-24. Get the full timeline:

Most recent: Clinical Trial Update: First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer [Phase 1]

See pricing